Latest Corporate Disclosures in Japan

Consolidated Financial Results for the Fiscal Year Ended December 31, 2025(Under Japanese GAAP)

FY2025 Full-Year Financial Results Briefing Material

Notice of Disclosure of Key KPI (Breakdown by Area)

[Delayed]Notice Regarding Commencement of the Tender Offer for Shares of Takara Bio Inc. (Securities Code: 4974)

Notice Regarding the Completion of Submission of the Semi-Annual Report for the Fiscal Year Ending March 31, 2026

(Summary) Notice Concerning Expression of Opinion in Support of Tender Offer for Company Shares by Takara Holdings, and Recommendation to Tender Share

Nxera Pharma Proposes Changes to its Board of Directors

[Updated]Consolidated Financial Results for the Nine Months Ended December 31, 2025 [Under Japanese GAAP]

Fiscal Year Ending March 2026 Q3 Financial Results Presentation Material

Notice Concerning the Formulation of Recurrence Prevention Measures (Outline)

Consolidated Financial Summary under Japanese GAAP for the First Three Months of the Fiscal Year Ending September 30, 2026

Consolidated Financial Results (Under IFRS)For the Second Quarter of the March 31, 2026 Fiscal Year

Notice Regarding Revision of Full-Year Financial Forecast

(Corrections) Notice Concerning Changes of Representative Directors, and Changes of Executive Officers and Important Employees

Non-consolidated Financial Results for the Nine Months of the Fiscal Year Ending March 31, 2026

Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 (Under Japanese GAAP)

Notice of Expression of Our Opinion in Favor of Tender Offer for Company’s Share Certificates by KOHNAN SHOJI Co., Ltd.

1Q FY2026 Presentation Material

Fiscal Year Ending September 2026 Consolidated Financial Results for the First Quarter [IFRS]

Consolidated Financial Results for the Nine Months of the Fiscal Year Ending March 31, 2026 (Under Japanese GAAP)